ShenZhen GTJA Investment Group was founded in 2001

ShenZhen GTJA Investment Group

Harvest Global Investments Limited (“HGI”) was established in Hong Kong as a wholly owned subsidiary of Harvest Fund Management.

Harvest Global Investments

Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.

Med-Fine Capital

Established in 1995 as the first joint venture investment bank in China, China International Capital Corporation Limited (CICC) is a leader in providing comprehensive financial services including investment banking, capital markets, institutional and individual securities sales and trading, fixed income, asset management, private equity, individual wealth management and research.

CICC

Incorporated in February 2009, Beijing E-Town International Investment & Development Co., Ltd ( E-Town Capital ) is a State-owned investment and financing company with the mission of promoting industrial upgrading and technological innovation in Beijing Economic-Technological Development Area (BDA for short). Oriented to real economy industrial development and adhering to financing service innovation, E-Town Capital has since its foundation combined the resources of both government and the market to constantly build platforms for diversified industrial investment as well as all-round financial service. It has established many professional subsidiaries including Beijing E-Town International Industrial Investment Management Co., Ltd., Beijing E-Town International Guarantee Co., Ltd., Beijing E-Town International Small-credit Co., Ltd., Beijing Mobile E-Town Co., Ltd. and E-Town International Holding (Hong Kong) Co., Ltd. E-Town Capital was assigned by the Beijing municipal government as one of the five management institutions for municipal-level pooled equity investment funds. E-Town Capital practices long-term strategic investment and runs an all-around and total access Beijing E-Town Parent Fund Business System. It has also made overseas acquisitions of Nexteer Automotive, ISSI, and Mattson Technology Inc. and invested in the SMIC Phase II & Ⅲ project of the BOE and BAIC Group, which promotes the agglomeration of high-end industries, including integrated circuits, equipment manufacturing, and aerospace technology. By the end of June 2018, E-Town Capital has invested in 116 projects, with a total investment of more than 35.4 billion yuan ($5.10 billion). Its parent fund system owns nearly 60 funds in total and participates in the management of funds of more than 250 billion yuan. E-Town Capital gradually refines its finance service, including financial assurance, financial leasing, and petty loans; upgrades product systems and serves the innovative development of small and medium-sized enterprises. It has developed a base for industrial agglomeration and innovative incubators by building special zones, such as Beijing Mobile E-Town and E-Startup. Beijing E-Town International Industrial Investment Management Co., Ltd. was inaugurated in 2013 with registered capital of 1,000 million yuan. The company is a professional industrial investment management enterprise in the finance service system and focuses on the construction of strategic emerging industries funds, such as integrated circuits, biological medicine, equipment manufacturing, aerospace technology. Founded on February 5, 2010, Beijing E-Town International Financing Guarantee Co., Ltd., with registered capital of 1.3 billion yuan, is a government-led policy-oriented loan guarantee company and one of the first companies to obtain a 5-year business license from the Beijing Municipal Bureau of Financial Work. Founded in 2013, Beijing E-Town Financing Leasing Co., Ltd. with registered capital of $120 million, is the first Sino-foreign joint venture financial leasing company in the Beijing Economic-Technological Development Area. Beijing E-Town International Small-credit Co., Ltd. is the BDA's first small-credit company approved by the Beijing Municipal Bureau of Finance Work. As a construction platform of E-Town Capital’s industrial bases, Beijing Mobile E-Town Co., Ltd. focuses on the investment and development, investment promotion, and operation and management of the Mobile E-Town Park and offers innovative incubator services. In the future, E-Town Capital will stick to the business idea of “internationalization, marketization, and innovation” and use capital as a linkage to offer all-around financial service by integrating all kinds of data including information related to capital, technology, talents, and markets. The company is striving to become an investment group with international influence.

Beijing E-town International Investment & Development

CITIC Securities Co., Ltd. (CITICS) was incorporated in Beijing on October 25, 1995.Upon approval of Chinese Securities Regulatory Commission (CSRC) on December 13, 2002, CITICS undertook an initial public offering (IPO) of 400 million common A shares. On January 6, 2003, CITICS (Ticker: 600030) was listed on the Shanghai Stock Exchange.   Its parent company is CITIC Group.  CITICS offered 334 million A shares August 31, 2007 and raised about RMB 25 billion, became the largest IB in China by capital. As of the end of 2010, CITICS' total assets amounted to RMB153.2 billion, with net asset at RMB70.4 billion.  CITICS holds controlling stakes in six subsidiaries and as of the end of 2010, and in consolidated terms, it has 149 branches in China (incl. Hong Kong).  CITICS maintains the leading position on business fronts such as investment banking, brokerage, asset management, investment advisory service, etc. and has already been providing diversified quality financial services and products by prioritizing the demand of clients and making the best of the powerful franchise, rich client bases and smooth market intelligence sharing.

CITIC Securities

LYZZ Capital is a venture capital firm specialized in seed, early, and expansion stage venture investments.

LYZZ Capital

SDIC Fund Management is a private equity that manages funds and raises nearly 60 billion yuan at present.  The management funds cover financial institutions, social security funds, state-owned and private capital, and it is one of the largest professional private equity management institutions in China.

SDIC Fund Management

BOCOM International is the the only well-known securities and financial services-related financial services platform in Hong Kong for the state-owned joint-stock commercial bank Bank of Communications. Founded in 1998, we are one of the first licensed securities companies with a background in China. We have experienced many economic and industry cycles and regulatory reforms. Our goal is to provide our customers with one-stop securities and financial services to expand their global business. With the long-established customer base, extensive brand recognition and industry expertise of Bank of Communications in Hong Kong and Mainland China, we are able to leverage our competitive edge to increase customer loyalty and create value for our customers and shareholders.

BOCOM International

Guangzhou Yuexiu Financial Holdings Group Co. , Ltd.  (formerly known as ''Guangzhou Friendship'', stock code 000987) was listed in the main board of Shenzhen Stock Exchange in 2000. In April of 2016, the company managed to raise ¥10 billion for the acquisition of 100% equity of Guangzhou Yuexiu Financial Holdings Group Co. , Ltd. through a private placement. Meanwhile, it was transformed from a single department business to the business model of focusing on 2 main areas including Finance and Department Store. On August 1st, 2016, the company's security abbreviation was changed to ''YXFHC'' and became the first local financial holdings listed platform in China. By the end of 2016, its total market capitalization reached ¥32.2 billion, ranking 324th among the top 500 listed companies of China; its total assets reached ¥66.853 billion which was nearly 20 times compared with the size by the end of 2015. The company's gross revenue was ¥5.741 billion, increasing by 104.73% year on year. The net profit attributing to shareholders of the listed company was ¥620 million.

Guangzhou Yuexiu Financial Holdings

Lake Bleu Capital is a Hong Kong-based investment platform that specializes in healthcare.

Lake Bleu Capital

Sealand Securities is an investment securities brokerage company. They offer corporate financial services, retail wealth management, asset management, sales transactions, research business, internet finance, and margin financing. Their corporate financial services business provides corporate financial services throughout the life cycle, including equity financing, debt financing, mergers, and acquisitions.

Sealand Securities

Houji Capital focuses on growth stage investments.

Houji Capital

Mabworks

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

MabWorks is a Chinese biopharmaceutical company focused on developing antibody-based therapeutics. The company is involved in the research, development, and manufacturing of monoclonal antibodies for various therapeutic applications. MabWorks has been particularly active in developing treatments for infectious diseases. In 2015, the company played a role in the development of MIL77, an antibody cocktail designed to treat Ebola virus disease. MIL77 was described as a near copy of ZMapp, an anti-Ebola antibody treatment originally developed with support from US and Canadian military research agencies. MabWorks, along with another Chinese company Hisun, claimed the development of MIL77 was motivated by the need to address a global health emergency and was supported by the Chinese government. The company has been involved in collaborative research efforts, including studies comparing MIL77 and ZMapp for protection against Ebola virus variants.

China Cancer Antibodies Market Trends & Clinical Trials Report 2023: Antibodies Pipeline is Still in the Expansion Phase as Global and China Drug Developers are Continuously Foraying into the Market

growing Duoning Biotech seeks winning formula for pricey IPO

Two Chinese virologists in the Canadian National Lab are CCP spies serving PLA’s bioweapon program

Bringing Life-Saving Biologics to More Patients

Biosimilars

MabWorks is a Chinese biopharmaceutical company focused on developing antibody-based therapeutics. The company is involved in the research, development, and manufacturing of monoclonal antibodies for various therapeutic applications. MabWorks has been particularly active in developing treatments for infectious diseases. In 2015, the company played a role in the development of MIL77, an antibody cocktail designed to treat Ebola virus disease. MIL77 was described as a near copy of ZMapp, an anti-Ebola antibody treatment originally developed with support from US and Canadian military research agencies. MabWorks, along with another Chinese company Hisun, claimed the development of MIL77 was motivated by the need to address a global health emergency and was supported by the Chinese government. The company has been involved in collaborative research efforts, including studies comparing MIL77 and ZMapp for protection against Ebola virus variants.
Key customers and partnerships
MabWorks has engaged in partnerships with government entities and research institutions in China. The company collaborated with the Chinese Academy of Sciences and the Academy of Military Medical Sciences on the MIL77 project. In 2016, MabWorks was listed as an author on a study examining the efficacy of MIL77 and ZMapp against Ebola virus, alongside researchers from US and Canadian institutions. The company has also worked with Hisun, another Chinese pharmaceutical firm, in the development and manufacturing of antibody treatments.

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Coherus Biosciences

Custom Biologics is a Canadian contract research organization (CRO) specializing in bioanalytical services for biopharmaceuticals, vaccines, and cell and gene therapy products. With over 20 years of experience, the company focuses on designing and validating regulatory compliant assays for functional characterization, potency/bioactivity assessments, clinical pharmacokinetics, and immunogenicity of biotherapeutic drugs. Custom Biologics' genomics group develops molecular genetic assays for gene and genome analysis, measuring genetic inserts and transgenes in gene therapy vectors, oncolytic viruses, and nucleic acid-based vaccines. The company has also developed a proprietary isothermal nucleic acid amplification technology called DASL-RAPID for rapid identification of human and food-borne pathogens. Custom Biologics maintains a Health Canada cGMP Drug Establishment License and operates under a quality system based on FDA and EMEA GLP guidelines. The company's services are utilized in preclinical research and development programs, as well as for validated GMP-compliant assays suitable for stability analysis, clinical analysis, and clinical/market lot release testing. Custom Biologics employs state-of-the-art bioanalytical laboratory equipment and sophisticated statistical software to generate data for submissions to regulatory agencies worldwide.

Custom Biologics

CuriRx, Inc., founded in 2012, is a contract development and manufacturing organization (CDMO) based in Wilmington, Massachusetts. The company specializes in providing end-to-end support for biotherapeutic drug developers, focusing on complex molecules such as recombinant proteins, monoclonal antibodies, bispecific antibodies, vaccines, antibody drug conjugates, oligonucleotides, and gene therapy products. CuriRx's services encompass upstream and downstream process development, optimization, characterization, scale-up and scale-down, analytical development, formulation development, and lyophilization.
In January 2022, CuriRx launched its Advanced Bioprocessing and Analytical Center, which combines state-of-the-art bioprocessing laboratories with the CuriLytics Platform's high-resolution analytical instrumentation. This center aims to accelerate biotherapeutic drug development by leveraging the team's extensive bioprocessing experience and employing the latest methods in upstream and downstream process development. The CuriLytics Platform utilizes high-resolution mass spectrometry and various orthogonal characterization methods to further de-risk drug development.
CuriRx has the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. The company's key personnel have been involved in successful development projects for notable drugs such as HUMIRA, SYNAGIS, BLINCYTO, and GATTEX. In September 2013, CuriRx was awarded a five-year contract by the National Cancer Institute for the development and production of oncology products, demonstrating its expertise in the field.

CuriRx

Paras Biopharmaceuticals Finland Oy is a biopharmaceutical technology development company based in Oulu, Finland. Founded in 2012, the company specializes in the development and manufacturing of complex biologics and biosimilars using microbial expression systems. Paras Biopharmaceuticals operates a state-of-the-art 25,000 square foot biologics production facility in Finland, which includes 4,300 square feet of classified cleanroom space. The facility is equipped for media and buffer preparation, fermentation, harvest and extraction, purification, final filtration, and freeze-drying.
The company's core activities are divided into two main divisions: Paras Biopharma, which focuses on biologics Contract Development and Manufacturing Organization (CDMO) services, and Paras Biologics, which handles biosimilar development and licensing. Paras Biopharmaceuticals has developed proprietary technology platforms including Biomultifold, Noblecleav, and Cytofold StructQuant to achieve high productivity and quality in biologics manufacturing. These technologies enable the company to produce complex proteins and biosimilars cost-effectively at scale.
As of December 2022, Paras Biopharmaceuticals reported achieving success with "Continuous Biomanufacturing" for high-value onco-immunology and urology biosimilars. The company has also made advancements in maximizing recombinant protein expression in microbial systems, reporting expression levels of up to 12g/L or more of fully folded, biologically active protein in fermentation broth as of July 2023.

Paras Biopharmaceuticals

Kashiv Biosciences, LLC is a fully integrated biopharmaceutical company focused on developing biosimilars and specialty biopharmaceutical products. The company has global research and development, clinical, regulatory, and manufacturing capabilities. Kashiv utilizes its MayaBio reactor technology to develop biosimilars. The company's product portfolio includes biosimilars targeting conditions such as asthma, chronic idiopathic urticaria, and neutropenia. Kashiv's lead biosimilar candidate, ADL018, is a proposed biosimilar to Xolair (omalizumab) currently in Phase III clinical trials for chronic spontaneous urticaria. In March 2022, Kashiv received FDA approval for its first biosimilar RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. The company has a robust pipeline of seven biosimilars and multiple 505(b)(2) and complex peptide generic products in development. Kashiv operates FDA-approved GMP manufacturing facilities in Chicago, Illinois and has state-of-the-art R&D infrastructure in Ahmedabad, India. The company is headquartered in Piscataway, New Jersey.
Key customers and partnerships
Kashiv has established strategic partnerships to commercialize its products globally. In October 2023, Kashiv entered into an exclusive licensing agreement with Alvotech for the development and commercialization of ADL018 in Europe, the UK, Australia, Canada, and New Zealand. In July 2024, Kashiv signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018 in the US. Kashiv has also collaborated with Amneal on the development and commercialization of other biosimilars, including RELEUKO and FYLNETRA. These partnerships allow Kashiv to leverage its partners' commercial expertise and global reach to bring its biosimilar products to market.

Kashiv Biosciences

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

AI/ML-driven technology platforms support drug design and development process and integration of drug substance development

Mabworks

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless